Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 21;9:12184. doi: 10.1038/s41598-019-48570-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Outcome analyses in TNBC and HER2+ disease. Signature classes <8% are excluded from multivariable analysis. If not stated, the reference group is the low-risk group for a signature. (A) Forest plot displaying hazard ratios (HR) with 95% confidence interval for respective signature class from multivariable Cox regression analysis using tumor size, patient age, lymph node status, and tumor grade as covariates in the 239 TNBC tumors with adjuvant chemotherapy. Significant classes marked (sig). For several signatures only one class existed, thus no values were calculated. Right: selected Kaplan-Meier plots for the TNBCtype and Genius signatures in these cases. (B) Kaplan-Meier plots of PAM50 subtypes defined through the single sample predictor AIMS or a centroid-based approach in HER2+/ER− disease treated with combined HER2-blocade and adjuvant chemotherapy. (C) Kaplan-Meier plots of PAM50 subtypes defined through the single sample predictor AIMS or a centroid-based approach in HER2+/ER+ disease treated with combined HER2-blocade, endocrine therapy, and adjuvant chemotherapy. ACT: adjuvant chemotherapy. Endo: endocrine treatment. P-values in Kaplan-Meier plots were calculated using the log-rank test.